CompletedPhase 4

Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus

Lead sponsor

Command Hospital, India

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 1 diabetes

Eligibility highlights

Primary endpoint

•Insulin requirement

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01235819

Org study IDDM/CHCC/03/2010

Timeline

Milestones

Study first posted2010-11-08estimated

Last update posted2016-07-27estimated

Study start2010-11 (month precision)

Primary completion2011-09actual (month precision)

Study completion2011-09actual (month precision)

Assets

Investigational agents

Exenatide

Who this study enrolls

Type 1 diabetes

Who can enroll

Minimum age12 Years

Maximum age30 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•T1DM <3 months

•GAD Antibody+ or Stimulated C peptide<0.5 ng/ml

•Ketosis at onset

•Age < 30 yr

Exclusion criteria

•Age > 30 yr

•Pancreas disease

•Significant systemic disease

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

change in insulin requirement

Time frame:one year

change from baseline, improvement

Secondary/protocol endpoint

C peptide response

Time frame:at the end of one year

C-peptide AUC

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
Diabetes research and clinical practice2013 May (month)PMID23490599doi:10.1016/j.diabres.2013.01.020via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.